Department of Surgery, NYU School of Medicine, New York, NY, U.S.A.
Pancreatic Cancer Center, Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, U.S.A.
Clin Sci (Lond). 2021 May 28;135(10):1289-1293. doi: 10.1042/CS20210181.
Pancreatic ductal adenocarcinoma (PDAC) features a hostile tumor microenvironment (TME) that renders it remarkably resistant to most therapeutic interventions. Consequently, survival remains among the poorest compared with other gastrointestinal cancers. Concerted efforts are underway to decipher the complex PDAC TME, break down barriers to efficacious therapies and identify novel treatment strategies. In the recent Clinical Science, Li and colleagues identify the long noncoding RNA KLHDC7B-DT as a crucial epigenetic regulator of IL-6 transcription in PDAC and illustrate its potent influences on the pancreatic TME. In this commentary, we introduce epigenetics in pancreatic cancer and put the findings by Li et al. in context with current knowledge.
胰腺导管腺癌 (PDAC) 的特点是其肿瘤微环境 (TME) 具有很强的敌意，使其对大多数治疗干预措施具有显著的抵抗力。因此，与其他胃肠道癌相比，其存活率仍然是最差的。目前正在进行协同努力，以破译复杂的 PDAC TME，突破有效治疗的障碍，并确定新的治疗策略。在最近的临床科学研究中，Li 和同事发现长非编码 RNA KLHDC7B-DT 是 PDAC 中 IL-6 转录的关键表观遗传调节剂，并阐明了其对胰腺 TME 的强大影响。在这篇评论中，我们介绍了胰腺癌中的表观遗传学，并将 Li 等人的研究结果与当前的知识联系起来。
